A spin-out of Tulane University, BioAesthetics was founded with the primary objective of improving reconstruction options for breast cancer patients after they have undergone mastectomies. The firm's tissue-engineered nipple-areolar complex (NAC) - a patent-pending product currently in the pre-clinical phase - is being designed such that it can be provided to plastic and reconstructive surgeons as an off-the-shelf ready, acellular, NAC graft. During the breast reconstruction phase - following a mastectomy - the approach is to make it possible for the surgeon to engraft the NAC graft in position onto the patients reconstructed breast. The intent is that the patients body would then use this NAC graft as a building frame to regenerate their own NAC. In 2017 BioAesthetics was accepted into IndieBio, a major biotech accelerator, located in San Francisco, CA. While at IndieBio BioAesthetics closed its Series Seed in Q4, 2017. In Q2, 2018, BioAesthetics headquarters was relocated to Research Triangle Park, North Carolina, to take advantage of the areas talent and deep biotech roots. The company is currently commercializing its inaugural product: a tissue-engineered nipple-areolar complex graft (NACgraft). BioAesthetics is focusing its product pipeline on acellular regenerative grafts for advanced wound and reconstructive care.
